Among these agents, those that have been shown to effectively target FGFR2 in GC models are the FGFR2-targeting PROTACs DGY-09–192 (which also targets FGFR1) [121], and LC-MB12 [122], which comprise the FGFR inhibitor infigratinib linked to recruiters of the E3 ubiquitin ligases VHL or cereblon, respectively. This evidence concerns the gene FGFR2 and gastric cancer.